Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cadrenal Therapeutics, Inc.

19.09
+1.649.40%
Post-market: 19.090.00000.00%19:04 EDT
Volume:45.66K
Turnover:824.03K
Market Cap:35.88M
PE:-2.70
High:19.09
Open:17.73
Low:17.19
Close:17.45
Loading ...

Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
14 Mar

Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate

Benzinga
·
14 Mar

Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Dow Jones
·
14 Mar

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…

Zacks Small Cap Research
·
07 Mar

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug

MT Newswires Live
·
04 Mar

BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott

Reuters
·
04 Mar

Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials

THOMSON REUTERS
·
04 Mar

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad

THOMSON REUTERS
·
04 Mar

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Business Wire
·
04 Mar

Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds

TIPRANKS
·
06 Feb

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

THOMSON REUTERS
·
06 Feb

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Business Wire
·
06 Feb

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Business Wire
·
05 Feb

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Business Wire
·
09 Jan

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in Lvad and Other Rare Cardiovascular Indications

THOMSON REUTERS
·
31 Dec 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Business Wire
·
31 Dec 2024